Global Invasive Fungal Infection Treatment Market - 2024-2031

Overview

The global invasive fungal infection treatment market reached US$ 10.6 billion in 2023 and is expected to reach US$ 14.6 billion by 2031, growing at a CAGR of 4.1% during the forecast period 2024-2031.

Invasive fungal infection (IFI) is one of the most common nosocomial infections and may result in invasive diseases in patients with various underlying diseases or other host factors. Invasive Fungal Diseases (IFD) are frequent infectious complications of hematopoietic stem cell transplantation.

Invasive Fungal Infections (IFIs) arise when fungi invade the body's deep tissues or organs. Invasive fungal infections have the potential to be fatal, in contrast to superficial fungal infections, which only affect the skin, hair, or nails. Directed antifungal treatment is used for patients with documented fungal disease.

Market Dynamics: Drivers & Restraints

Rising drug developments

Increasing drug developments against invasive fungal infections are expected to drive market growth during the forecast period. A large number of individuals are being affected by fungal infections and need effective drugs. Rising drug development increases the demand for new products and also serves the patients who are in need.

Several pharmaceutical companies are introducing a wide variety of treatment options that could treat invasive fungal infections. For instance, in September 2023, BDR Pharmaceutical launched the generic antifungal drug Zisavel (isavuconazole) for the treatment of infections like invasive aspergillosis and mucormycosis.

Additionally, in April 2023, Cidara Therapeutics and Melinta Therapeutics received U.S. FDA approval for Rezzayo (rezafungin for injection). This new medication is for the treatment and prevention of candidemia and invasive candidiasis in adults who have limited or no alternative treatment options.

Also, on January 29, 2024, Cidara Therapeutics, Inc. received the United Kingdom (U.K.) Medicines and Healthcare Products Regulatory Agency (MHRA) approval for REZZAYO (rezafungin acetate) for the treatment of invasive candidiasis in adults. Thus, the above factors are expected to drive market growth during the forecast period.

Consequences of immunosuppressive treatment

Antifungal activity of some immunosuppressive agents can lead to harmful microbiota changes and the selection of environmental species or isolates resistant to these drugs. Additionally, drug-drug interactions and genetic determinants of the patient might lead to suboptimal levels of drug accumulation and toxicity. Thus, the above factors are expected to hamper the market growth.

Market Segment Analysis

The global invasive fungal infection treatment market is segmented based on disease type, drug type, distribution channel, and region.

The triazoles segment is expected to dominate the market share

The triazoles segment is expected to dominate the market growth during the forecast period, this is due to the effectiveness of these drugs over invasive fungal infections. Triazoles perform effectively against many of the fungi that cause IFIs, such as Aspergillus, Candida, and some molds. Because of this, they provide a flexible first treatment option while medical professionals determine the exact type of fungus. Triazoles often have fewer adverse effects and a better safety profile than certain other antifungal groups.

For individuals with impaired immune systems who might already be coping with other medical conditions, this is crucial. Triazoles come in several forms, such as oral suspensions, intravenous solutions, tablets, and capsules. This makes it possible to use various treatment strategies based on the patient's state and the infection's severity. Triazoles have been used to treat IFIs for a long time. Thus, the above factors are expected to drive the market growth.

The growing number of alternative products is also expected to drive the segment growth. Pharmaceutical companies are increasingly providing a variety of triazole drugs which could help in the expansion of the segment growth.

For instance, in July 2021, Cadila Pharmaceuticals launched a new triazole antifungal drug Posaconazole, which is effective against a wide range of invasive fungal diseases. The drug has also been recommended as a second-line treatment for Mucormycosis or black fungus as it is commonly known. Thus, the above factors are expected to hold the segment in the dominant position.

Market Geographical Share

North America is expected to hold a significant position in the invasive fungal infection treatment market share

North America is expected to hold a dominant position in the invasive fungal infection treatment market due to the high prevalence of invasive fungal infection, and rising public awareness of invasive fungal diseases are some of the factors expected to boost the market in the forecast period.

For instance, according to the Centers for Disease Control & Prevention in 2024, it stated that candidemia is one of the most common bloodstream infections in the United States. An estimated 25,000 cases of candidemia occur in the United States each year.

Additionally, people get histoplasmosis in certain areas in the United States, particularly around the Mississippi and Ohio River valleys. Around 60-90% of people living in that area are exposed to Histoplasma in their lifetime. The increasing prevalence of invasive fungal infections in the region is expected to increase the demand for the drugs available. Thus, the above factors are expected to hold the region in the dominant position during the forecast period.

Market Segmentation

By Disease Type

Candidemia and Invasive Candidiasis

Intra-abdominal Candidiasis

Cryptococcal Meningitis

Esophageal Candidiasis

Histoplasmosis Acute Pulmonary

Invasive Aspergillosis

Invasive Rhinosinusitis

Mucormycosis

Others

By Drug Type

Polyenes

Amphotericin B deoxycholate

Lipid formulation amphotericin B.

Others

Triazoles

Fluconazole

Itraconazole

Posaconazole

Voriconazole

Others

Echinocandins

Anidulafungin

Caspofungin

Micafungin

Others

Flucytosine

Others

By Distribution Channel

Hospital Pharmacies

Retail Pharmacies

Others

By Region

North America

U.S.

Canada

Mexico

Europe

Germany

UK

France

Italy

Spain

Rest of Europe

South America

Brazil

Argentina

Rest of South America

Asia-Pacific

China

India

Japan

South Korea

Rest of Asia-Pacific

Middle East and Africa

Market Competitive Landscape

The major global players in the market include Merck & Co., Inc., Fresenius Kabi AG, Cidara Therapeutics Inc., Xellia Pharmaceuticals, Aark Pharmaceuticals., Intelicure Lifesciences, Taj Life Sciences Pvt Ltd, Angle Bio Pharma, Cadila Pharmaceuticals Limited and Stanex Drugs & Chemicals Pvt. Ltd. among others.

Key Developments

In January 2024, Fresenius Kabi introduced Posaconazole Injection, a generic substitute for Noxafil, for use in treating or preventing serious fungal infections in adults and children. It is also used to prevent invasive aspergillus and candida infections in patients who are severely immunocompromised, including adults and pediatric patients age 2 or older.

On March 6, 2024, the Food and Drug Administration approved the sale of the anti-fungal drug, Cresemba, for use against invasive aspergillosis and invasive mucormycosis.

Why Purchase the Report?

To visualize the global invasive fungal infection treatment market segmentation based on disease type, drug type, distribution channel, and region as well as understand key commercial assets and players.

Identify commercial opportunities by analyzing trends and co-development.

Excel data sheet with numerous data points of invasive fungal infection treatment market-level with all segments.

PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.

Product mapping available as Excel consisting of key products of all the major players.

The global invasive fungal infection treatment market report would provide approximately 53 tables, 47 figures, and 176 pages.

Target Audience 2024

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies